Loading...
•
Dec 31, 2021
Optinose Q4 2021 Earnings Report
Reported fourth quarter and full year financial results and recent operational highlights.
Key Takeaways
Optinose reported XHANCE net revenue of $22.5 million for the fourth quarter of 2021. The company's net loss for the quarter was $15.6 million, or $0.23 per share. They ended the year with $110.5 million in cash and cash equivalents.
XHANCE net revenue for Q4 2021 was $22.5 million.
Total revenues for the three months ended December 31, 2021 were $22.5 million.
Net loss for the three months ended December 31, 2021 was $15.6 million, or $0.23 per share.
Cash and cash equivalents totaled $110.5 million as of December 31, 2021.
Optinose
Optinose
Forward Guidance
Optinose expects XHANCE net revenues for the full year of 2022 to be at least $90 million and XHANCE average net revenue per prescription to exceed $210 for full year 2022.
Positive Outlook
- XHANCE net revenues for the full year of 2022 to be at least $90 million
- XHANCE average net revenue per prescription to exceed $210 for full year 2022.
- Top-line results from ReOpen2 expected in the second quarter of 2022
- Continued XHANCE prescription and net revenue growth
- Potential benefits of XHANCE for the treatment of chronic sinusitis
Challenges Ahead
- First quarter 2022 XHANCE net revenue will decrease compared to fourth quarter 2021
- XHANCE average net revenue per prescription for the first quarter of 2022 will decrease
- Early year effects on price and volume related to patient insurance
- Potential for varying interpretation of the top-line results from ReOpen1
- The prevalence of chronic sinusitis and market opportunities for XHANCE may be smaller than expected